# Mount Sinai Regional Drug Induced Liver Injury Network Site

> **NIH NIH U01** · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2020 · $65,902

## Abstract

Project Summary
 A major goal of DILIN since its inception has been to identify genetic biomarkers that predict
predisposition to DILI and a poor prognosis. DILIN has identified both drug specific and general
biomarkers for predisposition to DILI. The majority of these genetic biomarkers involve HLA
alleles.
 In the last several years, Dr. Nicoletti has been working extensively on the predisposition to
drug induced liver injury and recently joined the DILIN consortium. Dr. Nicoletti has been
actively involved in the ongoing DILIN genetic projects that profiled DILI cases based on HLA
alleles and common variants. She will continue to take an active role in carrying out the ongoing
GWAS and PrediXscan analyses. Given her extensive experience on HLA allele prediction
algorithms using both genotyped and sequencing data and extensive experience on the
subsequent association analyses at the level of HLA alleles, haplotypes, and HLA supertypes,
Dr. Nicoletti is also directing the design/analysis and interpretation of the results of the DILIN
HLA allele sequencing project in collaboration with Dr. Li, Dr. Chalasani, Dr. Barnhart, Dr.
Phillips and other DILIN researchers. Appropriate non-DILI control data will be critical to these
studies. These efforts led to several DILIN publications in the past year, but additional work
remains to be done.
 In the past year, Dr. Nicoletti expanded her efforts dramatically to provide non-DILI control data
and investigate genetic links between predisposition to DILI and other liver diseases. Dr.
Nicoletti is in the unique position of having immediate access to drug exposed and disease
controls via the Mount Sinai BioME Biobank, one of the largest biobanks, which has paired
genetic and clinical data for more than 50,000 individuals. This biobank is heavily weighted
towards those with liver disease since the liver division was the first to open its clinic patients to
enrollment in BioME. Finally, Dr. Nicoletti discovered evidence that DILI might share genetic risk
factors with other autoimmune liver diseases like primary biliary cirrhosis. By combining DILIN
genetic data with the BioMe dataset and other appropriate dbGAP datasets, she hopes to
evaluate the genetic similarity between DILI and other liver disease in order to better understand
the pathophysiology of DILI and the role of the genetic variants in the autoimmune traits.
Additional time and effort is needed to bring these studies to fruition. DILIN is requesting
another year of supplemental support for Dr. Nicoletti's efforts.

## Key facts

- **NIH application ID:** 10198195
- **Project number:** 3U01DK100928-08S1
- **Recipient organization:** ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
- **Principal Investigator:** Jawad Ahmad
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $65,902
- **Award type:** 3
- **Project period:** 2013-08-15 → 2023-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10198195

## Citation

> US National Institutes of Health, RePORTER application 10198195, Mount Sinai Regional Drug Induced Liver Injury Network Site (3U01DK100928-08S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10198195. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*